ライフサイエンスコーパス: cumulative incidence rate

1 Cumulative incidence rate/100,000 population (CIR) of ne

2 val, 33-37) and 8751 readmissions at 1 year (cumulative incidence rate, 185 readmissions/100 patients

3 thout SVR experienced liver failure (10-year cumulative incidence rate, 2.1%; 95% CI, 0.0%-4.5%; vs 2

4 2005 readmissions during the first 30 days (cumulative incidence rate, 35 readmissions/100 patients;

5 nd 76 without SVR who developed HCC (10-year cumulative incidence rate, 5.1%; 95% CI, 1.3%-8.9%; vs 2

6 Cumulative incidence rates among treated and untreated p

7 We estimated the cumulative incidence rate and used Cox proportional haza

8 analysis was used to compute the unadjusted cumulative incidence rates and adjusted relative risks o

9 Breast cancer cumulative incidence rates and age-specific standardized

10 We compared the cumulative incidence rates and case-mix adjusted rates o

11 The estimated cumulative incidence rates at 20 years for any second ma

12 The estimated 5-year cumulative incidence rates by failure category were: tot

13 With median 58 months' follow-up, 4-year cumulative incidence rate (CIR) for AML/MDS was 2.55% +/

14 Cumulative incidence rates (CIRs) of >/= grade 3 cervica

15 63 patients with HR-positive disease, 8-year cumulative incidence rates comparing trastuzumab versus

16 Cumulative incidence rates curves of PSA failure, define

17 The cumulative incidence rate difference between groups is -

18 Primary safety outcomes included cumulative incidence rates for (serious) adverse events.

19 Three-year cumulative incidence rates for any local, regional, or d

20 Cumulative incidence rates for CV event (atherosclerotic

21 We calculated cumulative incidence rates for invasive pneumococcal dis

22 Absolute 3-year Kaplan-Meier cumulative incidence rates for primary efficacy (23.4% v

23 here was a decline (P<0.001) in NMSC 10-year cumulative incidence rate in RTRs over the period 1994-2

24 y, we observed that the incidences of AESIs (cumulative incidence rate of 0.06%-0.09%) and mortality

25 frequent in the chlorambucil arm with 6-year cumulative incidence rate of 20.6% versus 3.7% in the fl

26 gen (HLA)-DQ2 homozygous individuals (8-year cumulative incidence rate of 35.4% vs maximum of the oth

27 2414 incident infections (2.9%), yielding a cumulative incidence rate of 9.11 cases per 100 person-y

28 [7.6] years; 1488 women [63%]), the adjusted cumulative incidence rate of a first medically treated f

29 The cumulative incidence rate of a second primary malignancy

30 1 years [range, 5 to 44 years]), the 15-year cumulative incidence rate of all-cause late mortality wa

31 In preterm-born children, the cumulative incidence rate of any mental and behavioral d

32 The cumulative incidence rate of COVID-19 was 0.112% in the

33 Cumulative incidence rate of first alcohol relapse was 2

34 The 10-year cumulative incidence rate of liver-related mortality or

35 At the 5-year follow-up, the cumulative incidence rate of MACE was 4.82% (95% CI, 3.8

36 The cumulative incidence rate of recurrent wheeze or asthma

37 The 8-year cumulative incidence rate of secondary malignancies was

38 The cumulative incidence rate of secondary sarcoma was radia

39 The cumulative incidence rate of serious infections was 1.45

40 The annual cumulative incidence rate of uveitis ranged from 102.2 t

41 benchmark case was established by utilizing cumulative incidence rates of agranulocytosis from a rec

42 The cumulative incidence rates of all-cause death were not s

43 The cumulative incidence rates of axillary, locoregional, an

44 The 5-year cumulative incidence rates of BCRL were 30.1%, 24.9%, 10

45 5-, 10-, 15-, and 20-year cumulative incidence rates of cardiac events were 2.2%,

46 g a former POW was associated with increased cumulative incidence rates of chronic disorders of the p

47 Cumulative incidence rates of COVID-19 did not differ fo

48 At 10 years, the cumulative incidence rates of CRC for individuals with n

49 eveloping colorectal cancer (CRC), since the cumulative incidence rates of CRC in IBD-patients diagno

50 The 6-month, 1-year, and 10-year cumulative incidence rates of developing an NPM after st

51 The cumulative incidence rates of disease-related complicati

52 Cumulative incidence rates of fractures were calculated

53 Cumulative incidence rates of grade 2 to 4 acute GVHD at

54 a history of subclinical social phobia, the cumulative incidence rates of heavy drinking and alcohol

55 2016, estimated 1- and 3-year posttransplant cumulative incidence rates of IAHEs were 2.7% (95% CI, 2

56 In the R0 surgery-alone arm, the cumulative incidence rates of local recurrence at 5 and

57 risk analyses, in LA and no LA arms, 5-year cumulative incidence rates of locoregional recurrence we

58 Cumulative incidence rates of LRR and CBC were 4.7% (95%

59 By 3 years, the cumulative incidence rates of mortality and readmission

60 The 3-month, 6-month, and 1-year cumulative incidence rates of NPM after diagnosis of sta

61 The 30-year cumulative incidence rates of peripheral arterial events

62 Cumulative incidence rates of persistent nonadherence (i

63 recurrent MI modeled as competing risks, the cumulative incidence rates of post-MI HF among patients

64 ateral or bilateral intermediate AMD, 5-year cumulative incidence rates of progression to advanced AM

65 In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreas

66 e versus placebo or observation, whereas the cumulative incidence rates of progression, death, or dea

67 The cumulative incidence rates of proven or probable invasiv

68 The cumulative incidence rates of relapse and treatment-rela

69 he epidemic wave, crude and age-standardized cumulative incidence rates of SARS-CoV-2 infection were

70 Cumulative incidence rates of second malignancies were c

71 The cumulative incidence rates of serious infections are rep

72 One- and 3-year cumulative incidence rates of severe IAHEs were 0.3% (95

73 n-Meier analyses, we calculated age-adjusted cumulative incidence rates of stroke.

74 The cumulative incidence rates of sudden death were assessed

75 Overall cumulative incidence rates of symptomatic VTEs were 15.1

76 f volume-reducing therapy and determined the cumulative incidence rates of volume-reducing therapy in

77 estimating the number of cases, prevalence, cumulative incidence, rate (particularly when the event

78 ffects as the incidence rate ratio (IRR) and cumulative incidence rate ratio (IRR(cum)).

79 Primary end points were cumulative incidence rate ratio (IRR) and mortality rate

80 We estimated cumulative incidence rate ratios (CIRR) and hazard ratio

81 Cumulative incidence rate ratios (IRRs) for treated vers

82 In 35 patients who could be evaluated, the cumulative incidence rate (+/-SE) of grade II to IV acut

83 The Kaplan-Meier curve of the cumulative incidence rate showed that the cumulative inc

84 The cumulative incidence rate was 2.2 percent (95 percent co

85 reated in 1307 women (2.2%), and the 10-year cumulative incidence rate was 3.29 (95% CI, 3.05-3.53).

86 57 patients with HR-negative disease, 8-year cumulative incidence rates were 24.0% versus 33.4% (P <

87 Ten-year cumulative incidence rates were 3% for renal replacement

88 ively, while the non-relapse mortality (NRM) cumulative incidence rates were 3.5% and 6.7%, respectiv

89 The 5-year primary event cumulative incidence rates were 45.8% for the chelation

90 Cumulative incidence rates were 5.1% (95% confidence int

91 Cumulative incidence rates were as follows: pediatric AH

92 Cumulative incidence rates were calculated for each year

93 Cumulative incidence rates were calculated using competi

94 were stratified by time since procedure, and cumulative incidence rates were calculated using random-

95 Cumulative incidence rates were significantly higher in

96 Cumulative incidence rates were virtually identical for

97 Cumulative incidence rates were weighted for non-respons

98 or MI or stroke were compared with estimated cumulative incidence rates with inverse probability weig